ewsba.se
Written by Eric Volkman for The Motley Fool->
The company also lifted its guidance for annual adjusted net income.
One of the healthier stocks in the healthcare sector on Wednesday was its retail king, CVS Health (NYSE: CVS). The company took the wraps off its first-quarter results, and investors were heartened by its performance. On the back of twin beats on key fundamentals, market players pushed CVS stock up by nearly 8% that trading day.
CVS reached nine-figure territory with that quarter's revenue, which came in slightly over $100 billion. That represented a year-over-year improvement of 6% -- fairly robust for a company as mature as this in the retail space.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Net income under generally accepted accounting principles (GAAP) leaped by 66% to slightly below $2.96 billion. On a non-GAAP (adjusted) basis, CVS's profitability was $2.57 per share, up from the year-ago result of $2.25.
Analysts underestimated the company's growth potential. For the quarter, their consensus revenue estimate was barely over $95 billion, while the collective adjusted earnings per share (EPS) expectation was $2.21.
In its earnings release, CVS said the recent success was driven by its strong presence in the pharmacy market and its unique structure. It quoted CEO David Joyner as saying that the company "continues to provide what people want most from healthcare: a connected, convenient, cost-effective engagement experience across our unique collection of businesses."
Compounding the very convincing double beat on analyst projections, CVS also raised its bottom-line guidance. It's now projecting adjusted EPS of $7.30 to $7.50, well up from the previous range of $7 to $7.20. As for revenue, management anticipates it will amount to at least $405 billion.
CVS is not only more prominent due to the collapse of longtime rival Rite Aid last year, but also benefits from a synergistic set of products and services for its customers, as Joyner said. On top of that, the U.S. population is getting older and in greater need of medications. I feel that as long as CVS continues on its current path and remains a tier above its competitors, its stock will do well.
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 950%* — a market-crushing outperformance compared to 203% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of May 6, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This data feed is not available at this time.